The first sign is often a subtle one, a missed connection in a child's gaze or a delayed response to their name. In a pediatrician's office, these fleeting moments can be the earliest clues to developmental risks like autism spectrum disorder (ASD). Yet in many parts of the world, the specialized tools and trained clinicians needed to spot them are scarce. Aignosis, a Jaipur-based healthtech startup founded in 2024, is betting that a standard laptop webcam and a few minutes of a child's attention can help bridge that gap [VCCircle, October 2026].
Its platform is not a diagnostic tool, a distinction the company and regulators are careful to maintain. It is a screening system, designed to analyze behavioral signals through computer vision and flag potential concerns for further clinical evaluation. For co-founders Raksheet Jain and Divyansh Mangal, the goal is to make early developmental risk assessment as accessible as the device it runs on [MediaNama, October 2026].
The clinic-in-clinic wedge
Aignosis operates on what it calls a clinic-in-clinic model. Instead of selling a standalone medical device, its software is deployed by pediatricians and healthcare providers within their existing practice. A child, aged 16 months to nine years, interacts with a series of nine specialized stimulus modules on a laptop screen while the built-in webcam records [IPO Platform, Unknown]. Advanced algorithms then analyze the video for behavioral markers, including eye gaze patterns, response to name, and reactions to facial expressions, generating a risk report for the clinician [VCCircle, October 2026].
The commercial and operational wedge is clear. By requiring no specialized hardware beyond a common laptop, the tool lowers the barrier to entry for clinics and public health systems. This has allowed Aignosis to secure a critical early beachhead: deployment across more than 20 government primary health centres in the state of Rajasthan [Economic Times Entrepreneur, October 2026]. The company has also reported expanding its reach to 125 schools [MediaNama, October 2026]. To date, it has conducted more than 8,000 screenings and is targeting at least 100,000 by the end of the current fiscal year [Gate, October 2026].
Regulatory steps and seed backing
Operating in the sensitive domain of pediatric health requires navigating a strict regulatory environment. Aignosis has reportedly received CDSCO Class B certification for its tool, a necessary clearance for its category in India [Gate, October 2026]. This regulatory milestone, alongside its early traction, helped attract a ₹4 crore (approximately $450,000) seed round in October 2026 [Economic Times Entrepreneur, October 2026].
The round was led by global early-stage investor Antler and prominent angel Nikhil Kamath. It included participation from a roster of well-known Indian founders and investors, including Varun Dua, Aman Gupta, Peyush Bansal, and GirnarSoft Ventures [Economic Times Entrepreneur, October 2026]. The capital is intended to fuel geographic expansion beyond Rajasthan into states including Punjab, Haryana, Tamil Nadu, and Karnataka [Gate, October 2026].
| Co-Founder | Background |
|---|---|
| Raksheet Jain | Holds a B.Tech in Artificial Intelligence from NMIMS Mumbai, a program developed in collaboration with Virginia Tech. Co-authored research on diabetic-retinopathy detection [VCCircle, October 2026]. |
| Divyansh Mangal | Holds a background in Physics from BITS Pilani and studied Quantum Information Technology at the University of Gdansk [VCCircle, October 2026]. |
The path to scale and inherent scrutiny
The ambition to scale a health AI tool from thousands to hundreds of thousands of screenings brings a predictable set of challenges. The most immediate is the need for rigorous, ongoing validation. Media reports have noted that publicly available materials did not provide error-rate data for the screening system [MediaNama, October 2026]. For any tool influencing a clinical pathway, especially in pediatrics, transparency around sensitivity, specificity, and performance across diverse populations is not just academic, it's foundational to trust and safe adoption.
The company's answer appears to be partnership-driven scale. It has teamed with Mankind Pharma, leveraging the pharmaceutical company's network of approximately 1,300 medical representatives to support screening camps with pediatricians across India [VCCircle, October 2026]. A partnership with the Apollo SHINE Foundation aims to further expand screening services [Gate, October 2026]. This asset-light, partnership-heavy model could accelerate deployment but also places a premium on consistent training and quality control across many third-party touchpoints.
- Clinical integration. The tool's success hinges on smooth workflow integration for busy pediatricians, not just technical accuracy.
- Data diversity. The AI models must perform reliably across India's vast genetic, linguistic, and cultural spectrum to avoid biased outcomes.
- Follow-up capacity. A screening tool is only as good as the diagnostic and support services available to the children it flags, a systemic challenge in under-resourced regions.
What standard care looks like today
For the population Aignosis serves, children aged 16 months to nine years at risk for developmental delays, the standard of care is often defined by its scarcity. In many regions, formal screening relies on observational checklists administered by general practitioners, with long wait times for specialist evaluation if a concern is raised. Gold-standard diagnostic tools require highly trained clinicians and are concentrated in urban tertiary care centers. This gap creates a diagnostic odyssey for families, where early intervention, which is critical for developmental outcomes, is delayed.
Aignosis is not aiming to replace that specialist. Its bet is that a scalable, accessible screening layer can make the pathway more efficient, helping direct limited clinical resources to the children who need them most. The next twelve months will test that bet, as the company works toward its goal of 100,000 screenings. Key milestones will be peer-reviewed validation of its tool's performance and the announcement of larger, institutional partnerships within state public health systems. For now, in more than twenty clinics in Rajasthan, a laptop webcam is watching, looking for a connection.
Sources
- [Economic Times Entrepreneur, October 2026] Aignosis raises ₹4 crore seed round led by Antler, Nikhil Kamath | https://entrepreneur.economictimes.indiatimes.com/news/funding/aignosis-raises-4-crore-seed-round-led-by-antler-nikhil-kamath/134609302
- [VCCircle, October 2026] Unveilr AI, Zaperon, Optimized Solutions, Aignosis raise funding | https://www.vccircle.com/unveilrai-zaperon-optimized-solutions-aignosis-raise-funding
- [Gate, October 2026] Antler Leads $417K Seed Round for Indian Healthtech Startup Aignosis | https://www.gate.com/en-us/news/detail/antler-leads-417k-seed-round-for-indian-healthtech-startup-aignosis-17888069
- [MediaNama, October 2026] AI autism screener expands from 20+ Rajasthan health centres to 125 schools, without public error rates | https://www.medianama.com/2026/10/223-ai-autism-screener-rajasthans-health-centres/
- [IPO Platform, Unknown] Aignosis company profile | https://www.ipo-platform.com/company/aignosis-jaipur
- [Indian Retailer, October 2026] Aignosis raises funding | https://www.indianretailer.com/article/technology/digital-trends/aignosis-raises-funding.a
- [Seedtable, Unknown] Aignosis, Funding, Investors & Team | https://seedtable.com/companies/aignosis